1. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients.
- Author
-
Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, and Armstrong AW
- Abstract
(1) Background: The purpose of this study is to compare the rate of COVID-19 vaccination among psoriasis patients internationally and to correlate it with their treatment regimens. (2) Methods: We conducted a cross-sectional study from January 2021 to October 2022 among adults in the United States (US), Chile, China, Switzerland, and Singapore using the Global Healthcare Study on Psoriasis survey. (3) Results: A total of 310 psoriasis patients in the US (98), Chile (32), China (80), Switzerland (39), and Singapore (61) were surveyed. Of these, 248 patients (80.0%) were vaccinated at least once for COVID-19 (Chile: 100%, Singapore: 100%, US: 93.9%, Switzerland: 69.2%, China: 45.0%). Compared with other countries, patients in China were 89% less likely to report at least one COVID-19 vaccination (1 - 0.11 = 0.89; OR 0.11; 95% CI: 0.03-0.48), and patients in Switzerland were 80% less likely (1 - 0.20 = 0.80; OR 0.20; 95% CI: 0.05-0.79). Compared with patients on biologics, patients on topicals were 10.9 (95% CI: 2.1-56.6) times more likely to report at least one COVID-19 vaccination, and patients on oral systemics were 7.2 times more likely (95% CI: 1.6-31.6). (4) Conclusions: Country of residence and treatment regimen are associated with different COVID-19 vaccination rates in psoriasis patients.
- Published
- 2024
- Full Text
- View/download PDF